A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
ASH-EHA Translational Research Training in Hematology is a unique, year-long training and mentoring program focused on helping junior researchers build successful careers in hematologic translational…
Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context…
The benefit of early palliative care in a resource-limited setting is not well understood. This study examined whether early palliative care could improve
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Overseeing the running of all aspects of the Society’s work, our Trustees are clinical experts with many years’ experience of working across all aspects of…
Cancer Gene Therapy – Mesenchymal stem cells as therapeutic vehicles for glioma